Skip to search formSkip to main contentSkip to account menu

idursulfase

Known as: Alpha-L-iduronate sulfate sulfatase, idursulfase [Chemical/Ingredient] 
National Institutes of Health

Related topics

Related topics

8 relations
3 ML idursulfase 2 MG/ML Injection [Elaprase]Alpha-glucosidaseIDS geneIDS protein, human

Narrower (1)

Elaprase

Broader (1)

Iduronate Sulfatase

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Biodistribution of Idursulfase Formulated for Intrathecal Use (Idursulfase-IT) in Cynomolgus Monkeys after Intrathecal Lumbar Administration
Enzyme replacement therapy with intravenous idursulfase (recombinant iduronate-2-sulfatase) is approved for the treatment of… 
2015
2015
Role of SD-OCT in the follow-up of a patient with macular edema associated with mucopoysaccharidosis type II (Hunter syndrome) undergoing idursulfase enzyme replacement therapy
Purpose Purpose: Mucopolysaccharidosis (MPS) type II (Hunter syndrome) is a variable, progressive, multisystem disorder… 
2014
2014
Impact of Enzyme Replacement Therapy on Linear Growth in Korean Patients with Mucopolysaccharidosis Type II (Hunter Syndrome)
Hunter syndrome (or mucopolysaccharidosis type II [MPS II]) arises because of a deficiency in the lysosomal enzyme iduronate-2… 
Review
2014
Review
2014
PO-0096 Clinical Effectiveness Of Idursulfase In Boys Aged 0–5 Years With Hunter Syndrome: 3-year Data From The Hunter Outcome Survey
Background and aims Symptoms of Hunter syndrome typically become apparent at 2–4 years of age. Previous analyses have… 
2014
2014
Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II
2012
2012
Successful noninvasive ventilation and enzyme replacement therapy in an adult patient with morbus hunter.
M. Hunter is characterized by an accumulation of mucopolysaccharides in cells, blood, and connective tissue as a consequence of a… 
2011
2011
Successful Desensitization to Idursulfase in a Patient with Type II Mucopolysaccharidosis ( Hunter syndrome )
Hunter syndrome or type II mucopolysaccharidosis is a rare lysosomal storage disease of X-linked recessive inheritance. It is… 
Review
2008
Review
2008
Idursulfase for the treatment of mucopolysaccharidosis II.
Human recombinant proteins are being used to treat an increasing number of disorders. Advances in the large scale production of… 
Review
2007
Review
2007
Idursulfase in Hunter syndrome treatment.
Hunter syndrome (mucopolysaccharidosis II, MPS II) is a rare X-linked lysosomal storage disorder caused by the deficiency of… 
Review
2007
Review
2007
[Clinical study of enzyme replacement therapy with idursulfase].
INTRODUCTION Important advances have been made in enzyme replacement therapy in the treatment of lysosomal diseases over the last… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)